Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE,…
LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…
First fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy…
BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of…
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete…
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase…
SAN CLEMENTE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in…
Dr. Newman also to give two presentations on the Company’s Decoy platform at the event to be held in Boston…
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present…
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001…